An in vitro study for the dosimetric and radiobiological validation of respiratory gating in conventional and hypofractionated radiotherapy of the lung: effect of dose, dose rate, and breathing pattern

Effectiveness of Flattening-Filter-Free versus Flattened Beams in V79 and Glioblastoma Patient-Derived Stem-like Cells

Literature data on the administration of conventional high-dose beams with (FF) or without flattening filters (FFF) show conflicting results on biological effects at the cellular level. To contribute to this field, we irradiated V79 Chinese hamster lung fibroblasts and two patient-derived glioblastoma stem-like cell lines (GSCs-named #1 and #83) using a clinical 10 MV accelerator with FF (at 4 Gy/min) and FFF (at two dose rates 4 and 24 Gy/min). Cell killing and DNA damage induction, determined using the γ-H2AX assay, and gene expression were studied. No significant differences in the early survival of V79 cells were observed as a function of dose rates and FF or FFF beams, while a trend of reduction in late survival was observed at the highest dose rate with the FFF beam. GSCs showed similar survival levels as a function of dose rates, both delivered in the FFF regimen. The amount of DNA damage measured for both dose rates after 2 h was much higher in line #1 than in line #83, with statistically significant differences between the two dose rates only in line #83. The gene expression analysis of the two GSC lines indicates gene signatures mimicking the prognosis of glioblastoma (GBM) patients derived from a public database. Overall, the results support the current use of FFF and highlight the possibility of identifying patients with candidate gene signatures that could benefit from irradiation with FFF beams at a high dose rate.

Does irregular breathing impact on respiratory gated radiation therapy of lung stereotactic body radiation therapy treatments?

The impact of irregular breathing on respiratory gated radiation therapy (RGRT) was evaluated for lung stereotactic body radiation therapy (SBRT) treatments. Measurements in the static mode were performed with different field sizes, depths of the measurements, breathing periods and duty cycles, using the Farmer ion chamber, PinPoint ion chamber, and microDiamond detector. The output constancy (OC) was evaluated between gated and nongated beams. Measurements in the dynamic mode for regular and irregular breathing in phase- and amplitude-gated modes, were performed with the amplitude of target motion from 5 mm to 25 mm, and breathing period from 3 to 6 s, for ion chamber, and film inserts. The dose discrepancy was evaluated for the ion chamber insert. The gamma passing rate was evaluated with film dosimetry. In the static mode, the maximum obtained OC was 0.8% using the Farmer ion chamber, 1% (p < 0.001) using the microDiamond detector, and 1.4% (p < 0.001) using the PinPoint ion chamber. In the dynamic mode, good agreement between planned and measured doses was obtained for regular breathing, 2.08 ± 0.48% (1.57 to 2.74%), which increased to 3.42 ± 1.24% (1.58 to 6.69%) for irregular breathing. The gamma passing rate of 3mm/3%, 3mm/2%, 3mm/1% and 2mm/2% was 99.4% ± 0.3, 98.2 ± 0.8%, 88.2 ± 3.0% and 96.4 ± 1.0% for regular and 97.2% ± 1.6%, 95.1 ± 2.6%, 85.6 ± 3.0% and 92.9 ± 2.9% for irregular breathing patterns (p < 0.01), respectively. For a slightly irregular breathing amplitude, lung SBRT cancer patients can be treated in the phase-gated mode.

In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response

•

Effect of RT dose rate modulation on immune response has never been evaluated.

•

Preclinical study using FFF RT technique in vivo and in vitro.

•

RT dose rate did not influence radio-immune response parameters.

•

We may modulate RT dose rate in association with immunotherapy without efficacy modification.

Introduction

Modern accelerators have the “flattening filter-free” (FFF) technique to deliver RT with a moderate high-dose rate, currently used in limited clinical indications. No scientifically established data are currently available on the possible effects of this high dose rate on the anti-tumor immune response. We therefore propose here to study these effects in a preclinical CT26 murine colorectal tumor model.

Material and methods

In-vitro, CT26 cells were irradiated on a Varian TrueBeam® linac at 3 different dose rates (4; 12 or 24 Gy/min) using the FFF mode. Activation of the anti-tumor immune response was evaluated by the analysis of induction of genes of the type I interferon pathway by RT-qPCR, and by the study of the induction of immunogenic death biomarkers. In-vivo, an efficacy study of RT delivering 16.5 Gy at 2 different dose rates was performed in immunocompetent Balb/c mice carrying CT26 syngeneic tumors, as well as an immunomonitoring analysed by flow cytometry and a transcriptomic analysis using RNA sequencing. Statistical analyzes were performed using non-parametric tests.

Results

In-vitro, no significant influence of an increase in FFF dose rate was shown for the induction of genes of the type I interferon pathway as well as for the studied immunogenic death markers (HMGB1 secretion). In-vivo, no difference in terms of tumor growth retardation between the 2 dose rates used was demonstrated, as well as for the composition of immune cell infiltrates within tumor microenvironment and the expression of immune checkpoints in immunomonitoring and RNAseq.

Conclusion

In this study involving the CT26 model, no influence of a moderate high dose rate in FFF technique on the anti-tumor immune response was demonstrated, which would make studies of associations between RT and checkpoint inhibitors fit with this technique of RT. However, further explorations using other cellular models seem to be of interest.